Key takeaways
- BPC-157 has no approval as a medicine from the FDA, the MHRA or the TGA.
- US: in Category 2 from September 2023 to 22 April 2026; an FDA advisory committee voted in favour of listing it on 23 July 2026; HHS has tolerated licensed compounding of BPC-157 acetate under ten conditions since 28 October 2026.
- Australia: Schedule 4 since 1 June 2024, and illegal to possess without authority under Appendix D, clause 5.
- Research-chemical sales are outside the US policy, and FDA has treated RUO-labelled peptides as unapproved drugs when sites showed human use.
- Sport: WADA class S0, prohibited at all times.
01How has BPC-157’s regulatory status changed since 2023?
BPC-157’s regulatory status has changed several times since 2023. One thing has not: no regulator in our three markets has approved it as a medicine.
| Date | Where | What happened | Source |
|---|---|---|---|
| Sep 2023 | US | FDA places BPC-157 (free base and acetate) in Category 2 of its interim 503A bulks policy, the category it uses for safety concerns (see FDA categories). | HHS Appendix B |
| 22 May 2024 | Australia | TGA final decision: BPC-157 added to Schedule 4 (prescription only) and to Appendix D, clause 5 (possession without authority is illegal). | TGA scheduling decision |
| 1 Jun 2024 | Australia | Schedule 4 listing takes effect. | TGA scheduling decision |
| 22 Apr 2026 | US | BPC-157 leaves Category 2. HHS later noted that neither the placement nor the removal changed its status under section 503A. | HHS Appendix B |
| 23 Jul 2026 | US | FDA’s Pharmacy Compounding Advisory Committee votes on BPC-157. FDA’s drug centre recommended against listing; the committee voted in favour. Reported count: 8 for, 6 against. | HHS Appendix B (outcome); The Washington Post (count) |
| 28 Oct 2026 | US | HHS files an enforcement-discretion policy covering BPC-157 acetate, with identity and route limits, under ten conditions. Published in the Federal Register on 30 Oct (91 FR 68526). | Federal Register; HHS Appendix B |
| 17 Nov 2026 | All | Still not an approved medicine in the US, UK or Australia. Still in WADA class S0. | WADA Prohibited List |
The vote count is from press reports. FDA had not posted minutes or a transcript of the meeting when we checked; see the 2026 PCAC vote.
02What is BPC-157’s status in the US now?
BPC-157 has no FDA approval and is not on the 503A bulks list. What changed on 28 October 2026 is enforcement. HHS says it does not intend to act against a state-licensed pharmacy, federal facility or licensed physician compounding BPC-157 acetate when ten conditions are met. They include a patient-specific prescription, an FDA-registered manufacturer, a certificate of analysis for the ingredient, a single active ingredient per product and adverse-event reporting.
The policy defines what it means by BPC-157: the acetate salt of the 15-residue sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.54 g/mol plus acetate. Appendix B also limits the dosage forms covered.
HHS gave three reasons for including it. Historical use “is now documented and quantified”. “A lot-specific certificate from an FDA-registered facility” now reports the identity, impurity, endotoxin, microbial and residual-solvent results that FDA’s drug centre had found lacking. And the policy’s own conditions address the risks through lot-level testing, single-ingredient products and MedWatch reporting. The policy is not binding, and HHS may revisit it if a safety or quality signal appears. For what the published human evidence on BPC-157 does and does not show, see our BPC-157 research guide.
Products sold online as research chemicals are outside this policy. FDA’s 2026 warning letters treated peptide products labelled “research use only” as unapproved new drugs where the seller’s website showed they were meant for people. More: peptides and US law and what “research use only” means.
03What is BPC-157’s status in the UK and Australia?
United Kingdom. BPC-157 has no UK marketing authorisation: WADA places it in class S0, which covers substances with “no current approval by any governmental regulatory health authority for human therapeutic use”. Under the Human Medicines Regulations 2012, a product presented as treating disease, or used to modify a physiological function by a pharmacological action, is a medicinal product, and an unauthorised one may not be sold or supplied. Detail: peptides and UK law.
Australia. BPC-157 has been a Schedule 4 prescription-only medicine since 1 June 2024. The proposal followed 48 referrals for importation of BPC-157 to the TGA since 1 July 2022. It is also in Appendix D, clause 5 of the Poisons Standard, “Poisons for which possession without authority is illegal”, and the October 2026 Standard keeps both entries. Sport Integrity Australia calls it “an experimental peptide that is not approved for use by any regulatory agency worldwide”. Detail: peptides and Australian law.
04Is BPC-157 banned in sport?
WADA’s Prohibited List names BPC-157 in class S0, non-approved substances, prohibited at all times, in and out of competition. None of the regulatory changes above affects that: a US compounding policy is not an approval by a health authority. Detail: peptides and anti-doping.
05What don’t we know about BPC-157’s status?
Whether FDA will list BPC-157. No proposed rule for the 503A bulks list had appeared in the Federal Register as of 17 Nov 2026.
The official vote record. FDA’s meeting page carries the briefing documents and questions, but not minutes or a transcript. The committee voted separately on the free base and the acetate; the press reports we rely on give one count.
How long the US policy lasts. Until BPC-157 is addressed in a final rule, unless HHS revisits it earlier.
Every change is logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.